| Literature DB >> 34095166 |
Yanjie Zhang1,2, Liye Zou3, Si-Tong Chen4, Jun Hyun Bae1, Dae Young Kim1, Xiaolei Liu5, Wook Song1,6.
Abstract
Background: Sarcopenia is a muscle disease in loss of muscle strength, mass, and function associated with aging. Although protective effects of exercise on muscle mass and function are generally recognized, research findings in sarcopenic adults are inconsistent. It is necessary to conduct a systematic review to determine the effects of exercise on muscle strength, body composition, and physical performance in older adults with sarcopenia, and to examine the potential moderators including sociodemographic characteristics and exercise-related factors.Entities:
Keywords: meta—analysis; muscle function; physical exercise; physical performance; sarcopenia
Year: 2021 PMID: 34095166 PMCID: PMC8169963 DOI: 10.3389/fmed.2021.649748
Source DB: PubMed Journal: Front Med (Lausanne) ISSN: 2296-858X
Figure 1Process of study selection following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA).
Characteristics of randomized controlled trials included in the meta-analysis.
| Chen et al. (2018) ( | Sarcopenia residents of community dwelling | 33 | 67.5 | 2 × 60 min/week | Waitlist | AWGS | BIA | Grip strength | No |
| Hassan et al. (2016) ( | Sarcopenia residents of nursing care facilities | 85.9 | 2 × 60 min/week | Usual care | EWGSOP | BIA | Grip strength | No | |
| I Iranzo et al. (2018) ( | Sarcopenia residents in institution | 28 | 81.9 | 3 × 30–40 min/week | Waitlist | EWGSOP | BIA | Grip strength | No |
| Jung et al. (2019) ( | Sarcopenia residents of community dwelling | 26 | 75 | 3 × 25–75 min/week | Usual care + | AWGS | DXA | Knee extension strength | No |
| Kim et al. (2012) ( | Sarcopenia residents of community dwelling | 117 | 79 | 2 × 60 min/week, | C1: Nutrition | AWGS | BIA | Knee extension strength | No |
| Kim et al. (2013) ( | Sarcopenia residents of community dwelling | 96 | 80 | 2 × 60 min/week, | C1: Nutrition | AWGS | BIA | Grip strength | No |
| Lichtenberg et al. (2019) ( | Sarcopenia residents of community dwelling | 78.5 | 2 × 50 min/week | Nutrition | EWGSOP | DXA | Grip strength | ||
| Mafi et al. (2019) ( | Sarcopenia residents of community dwelling | 47 | 68.5 | 3 × 60 min/week | C1: Nutrition | EWGSOP | DXA | TUG | No |
| Makizako et al. 2020 ( | Sarcopenia residents of community dwelling | 75 | 1 × 60 min/week | C1: Waitlist | AWGS | BIA | Grip strength | No | |
| Maruya et al. (2016) ( | Sarcopenia residents of community dwelling | 52 | 69 | 1 × 90 min/week, | Usual daily activity | AWGS | BIA | Grip strength | No |
| Piastra et al.(2018) ( | Sarcopenia residents of community dwelling | 72 | 70 | 2 × 60 min/week, | Postural activation | EWGSOP | BIA | Grip strength | No |
| Strasser et al. (2018) ( | Sarcopenia residents of institution | 33 | 83 | 2 × 60 min/week | Cognitive training | EWGSOP | DXA | SMI | No |
| Tsekoura et al. (2018) ( | Sarcopenia residents of community dwelling | 54 | 73 | E1: | Health education | EWGSOP | BIA | Grip strength | No |
| Vikberg et al. (2019) ( | Sarcopenia residents of community dwelling | 70 | 70.5 | 3 × 45 min/week, | Waitlist | EWGSOP | DXA | Grip strength | No |
| Wei et al. (2016) ( | Sarcopenia residents of community dwelling | 40 | 76 | 3 × 24 min/week | Waitlist | EWGSOP | BIA | No | |
| Yamada et al. (2019) ( | Sarcopenia residents of community dwelling | 84 | 83.9 | 2 × 30 min/week | C1: nutrition C2: waitlist | AWGS | BIA | Grip strength | |
| Zhu et al. (2019) ( | Sarcopenia residents of community dwelling | 77 | 73 | 2 × 45–60 min/ week | Waitlist | AWGS | DXA | Grip strength | No |
ASM, appendicular skeletal muscle; AWGS, Asia Working Group for Sarcopenia; EWGSOP, European Working Group on Sarcopenia in Older People; SMI, skeletal muscle mass index; BIA, bioelectrical impedance analysis; DXA, Dual-energy X-ray absorptiometry; TUG, Timed up and go.
Methodological quality of the included studies [The Physiotherapy Evidence Database (PEDro analysis)].
| Chen et al. 2018 ( | 6 | Good | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 1 |
| Hassan et al. 2016 ( | 6 | Good | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 1 |
| I Iranzo et al. 2018 ( | 6 | Good | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 1 |
| Jung et al. 2019 ( | 6 | Good | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 1 |
| Kim et al. 2012 ( | 7 | Good | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 1 |
| Kim et al. 2013 ( | 7 | Good | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 1 |
| Lichtenberg et al. 2019 ( | 7 | Good | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 |
| Mafi et al. 2019 ( | 6 | Good | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 1 |
| Makizako et al. 2020 ( | 7 | Good | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 |
| Maruya et al. 2016 ( | 5 | Fair | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 1 |
| Piastra et al. 2018 ( | 5 | Fair | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 1 |
| Strasser et al. 2018 ( | 6 | Good | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 1 |
| Tsekoura et al. 2018 ( | 6 | Good | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 1 |
| Vikberg et al. 2019 ( | 7 | Good | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 1 |
| Wei et al. 2016 ( | 6 | Good | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 1 |
| Yamada et al. 2019 ( | 7 | Good | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 |
| Zhu et al. 2019 ( | 8 | Good | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 |
Studies were classified as having excellent (9–10), good (6–8), fair (4–5), or poor (< 4).
Scale of item score: 0, absent; 1, present. The PEDro scale criteria are (1) eligibility criteria, (2) random allocation, (3) concealed allocation, (4) similarity at baseline on key measures, (5) subject blinding, (6) therapist blinding, (7) assessor blinding, (8) more than 85% follow-up of at least 1 key outcome, (9) intention-to-treat analysis, (10) between-group statistical comparison for at least one key outcome, and (11) point estimates and measures of variability provided for at least one key outcome.
Figure 2Forest plot showing the effects of exercise vs. control on muscle strength: (A) grip strength, (B) knee extension, (C) chair and stand test.
Synthesized results for the effects of exercise vs control intervention.
| Grip strength | 15 | 0.30 | 0.15–0.45 | 6 | 14.90 | 14 | 0.39 | 0.39 |
| Knee extension | 11 | 0.32 | 0.15–0.50 | 0 | 7.99 | 10 | 0.63 | 0.19 |
| Chair and stand | 8 | 0.56 | 0.30–0.81 | 36 | 10.95 | 7 | 0.14 | 0.86 |
| TUG | 9 | 0.74 | 0.48–1.00 | 31 | 11.63 | 8 | 0.17 | 0.01 |
| Gait speed | 17 | 0.59 | 0.35–0.82 | 62 | 41.74 | 16 | 0.001 | 0.01 |
| Skeletal mass index | 11 | 0.37 | 0.15–0.58 | 16 | 11.90 | 10 | 0.29 | 0.92 |
| ASM | 13 | 0.31 | 0.13–0.49 | 20 | 15.07 | 12 | 0.24 | 0.21 |
| Lean mass | 4 | 0.20 | −0.07 to 0.48 | 0 | 0.80 | 3 | 0.85 | 0.20 |
| Body fat | 5 | 0.24 | −0.04 to 0.53 | 3 | 4.12 | 4 | 0.39 | 0.15 |
| Fat-free mass | 3 | 0.36 | −0.10 to 0.82 | 0 | 0.36 | 2 | 0.84 | 0.39 |
ASM, appendicular skeletal muscle; SMD, standard mean difference; TUG, timed up and go; k, number of trials.
Figure 3Forest plot showing the effects of exercise vs. control on physical performance: (A) gait speed, (B) timed up and go test.
Figure 4Forest plot showing the effects of exercise vs. control on body composition: (A) skeletal muscle mass index, (B) appendicular muscle mass, (C) lean mass, (D) body fat, (E) fat-free mass.
Moderator analysis for the effects of exercise on measurement outcomes.
| AWGS | 0.23 (0.03–0.43) | 0.32 (0.13–0.51) | 0.55 (0.11–0.98) | 0.69 (0.26–1.13) | 0.55 (0.23–0.88) | 0.25 (0.05–0.44) | 0.18 (−0.13 to 0.49) | 0.08 (−0.21 to 0.36) | 0.53 (−0.25 to 1.31) | 0.36 (−0.18 to 0.91) |
| EWGSOP | 0.41 (0.15–0.67) | 0.34 (−0.10 to 0.78) | 0.54 (0.22–0.87) | 0.79 (0.43–1.16) | 0.64 (0.28–1.00) | 0.47 (0.00–0.94) | 0.49 (0.18–0.80) | 0.19 (−0.20 to 0.57) | 0.16 (−0.14 to 0.45) | 0.16 (−0.22 to 0.54) |
| Female | 0.39 (0.03–0.76) | 0.39 (0.12–0.66) | – | 0.91 (0.46–1.35) | 0.95 (0.59–1.31) | 0.25 (0.02–0.48) | 0.27 (−0.07 to 0.62) | 0.13 (−0.11 to 0.37 | 0.28 (−0.12 to 0.68) | 0.55 (−0.26 to 1.37) |
| Male | 0.97 (0.34–1.60) | – | – | 1.08 (0.35–1.81) | 0.39 (−0.22 to 0.99) | 0.94(−0.59 to 2.48) | 1.40 (0.73–2.06) | – | – | – |
| Mixed | 0.21 (0.03–0.39) | 0.28 (0.05–0.51) | 0.5 (0.30–0.81) | 0.26 (0.26–0.86) | 0.43 (0.15–0.70) | 0.27 (0.03–0.50) | 0.27 (0.02–0.52) | 0.001 (−0.68 to 0.68) | 0.13 (−0.25 to 0.52) | 0.13 (−0.20 to 0.46) |
| RT | 0.33 (0.14–0.51) | 0.32 (0.09–0.54) | 0.31 (0.02–0.61) | 0.80 (0.37–1.23) | 0.50 (0.19–0.81) | 0.33 (0.13–0.52) | 0.54 (0.15–0.74) | 0.11 (−0.11 to 0.34) | 0.16 (−0.14 to 0.45) | 0.16 (−0.17 to 0.49) |
| RT+AE | 0.24 (−0.02 to 0.50) | 0.35 (0.01–0.68) | 0.71 (0.33–1.08) | 0.59 (0.23–0.96) | 0.92 (0.35–1.50) | 0.19 (−0.25 to 0.64) | 0.18 (−0.20 to 0.55) | – | 0.53 (−0.25 to 1.31) | 0.50 (−0.42 to 1.42) |
| WBV | – | 0.34 (−0.29 to 0.96) | 0.88 (0.23–1.53) | 0.90 (0.25–1.55) | 0.61 (−0.02 to 1.25) | – | – | – | – | – |
| ≥3 times/week | 0.14 (−0.16 to 0.44) | 0.46 (0.07–0.85) | 0.72 (0.39–1.04) | 0.79 (0.43–1.16) | 0.85 (0.41–1.29) | 0.68 (−0.18 to 1.55) | 0.25 (−0.02 to 0.53) | 0.24 (−0.18 to 0.65) | 0.31 (−0.22 to 0.83) | |
| <3 times/week | 0.36 (0.16–0.55) | 0.29 (0.10–0.48) | 0.35 (0.06–0.64) | 0.69 (0.26–1.13) | 0.47 (0.19–0.85) | 0.26 (0.08–0.43) | 0.48 (0.06–0.90) | 0.11 (−0.11 to 0.34) | 0.18 (−0.19 to 0.55) | 0.23 (−0.23 to 0.68) |
| >12 weeks | 0.39 (0.12–0.65) | 0.33 (0.02–0.65) | 0.77 (0.11–1.44) | – | 0.38 (0.02–0.75) | 0.25 (−0.04 to 0.54) | 0.28 (−0.01 to 0.58) | 0.19 (−0.20 to 0.57) | 0.18 (−0.19 to 0.55) | 0.18 (−0.27 to 0.62) |
| ≤ 12 weeks | 0.27 (0.06–0.47) | 0.32 (0.11–0.53) | 0.44 (0.19–0.68) | 0.74 (0.48–1.00) | 0.63 (0.35–0.92) | 0.34 (0.11–0.57) | 0.43(0.08–0.79) | 0.08 (−0.21 to 0.36) | 0.24 (−0.18 to 0.65) | 0.34 (−0.17 to 0.86) |
| ≤ 45min | 0.14 (−0.09 to 0.37) | 0.31 (−0.07 to 0.68) | 0.44 (0.19–0.68) | 0.66 (0.25–1.06) | 0.55 (0.15–0.96) | 0.35 (0.05–0.64) | 0.29 (−0.01 to 0.59) | 0.12 (−0.37 to 0.61) | 0.07 (−0.31 to 0.46) | |
| >45min | 0.41 (0.19–0.65) | 0.34 (0.12–0.56) | 0.77 (0.11–1.44) | 0.82 (0.44–1.19) | 0.62 (0.33–0.92) | 0.30 (0.07–0.53) | 0.42 (0.04–0.79) | 0.11 (−0.11 to 0.34) | 0.24 (−0.09 to 0.58) | 0.43 (−0.04 to 0.90) |
| Light | 0.22 (−0.01 to 0.45 | 0.27 (−0.08 to 0.61) | 0.58 (0.03–1.20) | – | 0.24 (−0.11 to 0.59) | 0.31 (0.02–0.60) | 0.29 (−0.20 to 0.79) | – | – | 0.06 (−0.59 to 0.71) |
| Moderate-vigorous | 0.35 (0.09–0.61) | 0.38 (0.13–0.62) | 0.58 (0.26–0.90) | 0.81 (0.57–1.05) | 0.82 (0.48–1.16) | 0.32 (0.06–0.59) | 0.30 (0.03–0.56) | 0.11 (−0.11 to 0.34) | 0.18 (−0.189 to 0.552) | 0.16 (−0.22 to 0.54) |
| Vigorous | 0.50 (−0.37 to 1.37) | 0.43 (−0.35 to 1.20) | 0.33 (−0.16 to 0.82) | 0.23 (−0.26 to 0.71) | 0.44 (0.01 to 0.87) | 0.28 (−0.21 to 0.77) | 0.56 (−0.23 to 1.35) | – | 0.24 (−0.18 to 0.65) | 0.55 (−0.26 to 1.37) |
| Active | 0.30 (0.08–0.53) | 0.28 (0.01–0.54) | 0.31 (0.001–0.61) | 0.70 (0.41–1.00) | 0.76 (0.38–1.15) | 0.23 (0.04–0.41) | 0.48 (0.13–0.83) | 0.14 (−0.14 to 0.42) | 0.22 (−0.09 to 0.53) | 0.48 (−0.41 to 1.38) |
| Passive | 0.30 (0.07–0.53) | 0.38 (0.13–0.63) | 0.74 (0.41–1.06) | 0.85 (0.24–1.46) | 0.34 (0.12–0.56) | 0.61 (0.03–1.20) | 0.21 (−0.10 to 0.52) | – | 0.15 (−0.46 to 0.77) | 0.17 (−0.20 to 0.55) |
p < 0.05.
AE, aerobic exercise; ASM, appendicular skeletal muscle; AWGS, Asia Working Group for Sarcopenia; EWGSOP, European Working Group on Sarcopenia in Older People; RT, resistance training; TUG, timed up and go; WBV, whole-body vibration training.
Figure 5Effect sizes by percent of female participants in meta-regression for gait speed.
Meta-regression for continuous variables to predict exercise effects on measurement outcomes.
| Age | −0.0089 | −0.0110 | −0.0255 | 0.0069 | −0.0252 | −0.0134 | 0.0117 | −0.0210 | 0.0007 | 0.0023 |
| (−0.0364 to 0.0186) | (−0.0474 to 0.0254) | (−0.0765 to 0.0255) | (−0.0618 to 0.0759) | (−0.0758 to 0.0254) | (−0.0443 to 0.0174) | (−0.0249 to 0.0483) | (−0.0726 to 0.0306) | (−0.0438 to 0.0452) | (−0.0100 to 0.0146) | |
| Percent of female participants | −0.0021 (−0.0087 to 0.0045) | 0.0025 (−0.0078 to 0.0128) | 0.0018 (−0.0072 to 0.0438) | −0.0012 (−0.0094 to 0.0071) | 0.0096 (0.0006 to 0.0186) | −0.0051 (−0.0107 to 0.0004) | −0.0092 (−0.0162 to −0.0021) | 0.0144 (−0.0661 to 0.0949) | 0.0036 (−0.0098 to 0.0170) | 0.0096 (−0.0048 to 0.0240) |
| Exercise time per week in minutes | 0.0021 (−0.0014 to 0.0056) | 0.0021 (−0.0018 to 0.0060) | −0.0004 (−0.0083 to 0.0075) | 0.0016 (−0.0041 to 0.0072) | 0.0046 (−0.0009 to 0.0101) | 0.0024 (−0.0033 to 0.0082) | −0.0055 (−0.0124 to 0.0014) | — | −0.0011 (−0.0398 to 0.0179) | −0.0010 (−0.0110 to 0.0089) |
| Exercise duration | 0.0063 | 0.0011 | −0.0141 | −0.0292 | −0.0172 | −0.0037 | −0.031 | 0.0073 | −0.0012 | −0.0049 |
| (−0.0129 to 0.0255) | (−0.0305 to 0.0328) | (−0.0657 to 0.0378) | (−0.2068 to 0.1485) | (−0.0705 to 0.0362) | (−0.0255 to 0.0182) | (−0.0275 to 0.0213) | (−0.0150 to 0.0297) | (−0.0255 to 0.0231) | (−0.0522 to 0.0425) | |
| Dose of exercise intervention | 0.00000 (−0.0001 to 0.0001) | 0.0001 (−0.0001 to 0.0002) | 0.0001 (−0.0002 to 0.0003) | 0.0004 (−0.0005 to 0.0014) | 0.0001 (−0.0002 to 0.0003) | −0.0001 (−0.0002 to 0.0002) | −0.0001 (−0.0002 to 0.0001) | 0.0001 (−0.0001 to 0.0002) | −0.00001 (−0.0002 to 0.0002) | −0.00001 (−0.0003 to 0.0002) |
p < 0.05.
ASM, appendicular skeletal muscle; SMI, skeletal muscle mass index; TUG, timed up and go; –, the continuous variable in each study is equivalent.
Figure 6Effect sizes by percent of female participants in meta-regression for skeletal muscle index.